Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Texas Oncology- Denton South
mi
from
Denton, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Texas Oncology- Denton South
mi
from
Denton, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Texas Oncology- Lewisville
mi
from
Lewisville, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Texas Oncology- Lewisville
mi
from
Lewisville, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Texas Oncology Seton Williamson
mi
from
Round Rock, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Texas Oncology Seton Williamson
mi
from
Round Rock, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Texas Oncology - Sherman
mi
from
Sherman, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Texas Oncology - Sherman
mi
from
Sherman, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Texas Oncology-Tyler
mi
from
Tyler, TX
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Northern Utah Associates
mi
from
Ogden, UT
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Northern Utah Associates
mi
from
Ogden, UT
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Virginia Oncology Associates
mi
from
Newport News, VA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Virginia Oncology Associates
mi
from
Newport News, VA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Oncology and Hematology Associates of Southwest Virginia, Inc., dba Blue Ridge Cancer Care
mi
from
Roanoke, VA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Oncology and Hematology Associates of Southwest Virginia, Inc., dba Blue Ridge Cancer Care
mi
from
Roanoke, VA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
MD Anderson Cancer Center
mi
from
Orlando, FL
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
MD Anderson Cancer Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Henry Ford Health System
mi
from
Detroit, MI
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Centre d' Oncologie de Gentilly
mi
from
Nancy,
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Centre d' Oncologie de Gentilly
mi
from
Nancy,
Click here to add this to my saved trials
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated:  1/31/2017
Dr Michelle Young
mi
from
Phoenix, AZ
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated: 1/31/2017
Dr Michelle Young
mi
from
Phoenix, AZ
Click here to add this to my saved trials
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated:  1/31/2017
Dr Francesco Ramirez
mi
from
Scottsdale, AZ
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated: 1/31/2017
Dr Francesco Ramirez
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated:  1/31/2017
Dr David Gatof
mi
from
Lafayette, CO
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated: 1/31/2017
Dr David Gatof
mi
from
Lafayette, CO
Click here to add this to my saved trials
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated:  1/31/2017
Dr Michael Wallace
mi
from
Jacksonville, FL
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated: 1/31/2017
Dr Michael Wallace
mi
from
Jacksonville, FL
Click here to add this to my saved trials
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated:  1/31/2017
Dr Prateek Sharma
mi
from
Kansas City, KA
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated: 1/31/2017
Dr Prateek Sharma
mi
from
Kansas City, KA
Click here to add this to my saved trials
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated:  1/31/2017
Dr Marcia Canto
mi
from
Baltimore, MD
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated: 1/31/2017
Dr Marcia Canto
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated:  1/31/2017
Dr David Bruining
mi
from
Rochester, MN
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated: 1/31/2017
Dr David Bruining
mi
from
Rochester, MN
Click here to add this to my saved trials
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated:  1/31/2017
Dr Raf Bisschop
mi
from
Leuven,
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Status: Enrolling
Updated: 1/31/2017
Dr Raf Bisschop
mi
from
Leuven,
Click here to add this to my saved trials
Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing
Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing
Status: Enrolling
Updated:  2/6/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing
Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing
Status: Enrolling
Updated: 2/6/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
University of Southern California
mi
from
Los Angeles, CA
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
University of Colorado
mi
from
Denver, CO
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Emory University
mi
from
Atlanta, GA
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
University of Iowa
mi
from
Iowa City, IA
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
University of South Carolina
mi
from
Columbia, SC
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
University of South Carolina
mi
from
Columbia, SC
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
The University Of Texas
mi
from
Houston, TX
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
The University Of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Univ of Puerto Rico
mi
from
San Juan,
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Univ of Puerto Rico
mi
from
San Juan,
Click here to add this to my saved trials
Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Status: Enrolling
Updated:  2/13/2017
University of California-Davis
mi
from
Sacramento, CA
Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Status: Enrolling
Updated: 2/13/2017
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/14/2017
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/14/2017
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/14/2017
New Jersey Medical School-University Hospital Cancer Center
mi
from
Newark, NJ
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/14/2017
New Jersey Medical School-University Hospital Cancer Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/14/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/14/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/14/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/14/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/14/2017
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/14/2017
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/14/2017
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/14/2017
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/14/2017
Novartis Investigative Site
mi
from
Parkville,
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/14/2017
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Mayo Clinic
mi
from
Phoenix, AZ
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
UC San Diego Medical Center
mi
from
La Jolla, CA
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
UC San Diego Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
University of Miami
mi
from
Miami, FL
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Rush University Medical Center
mi
from
Chicago, IL
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
University of Chicago Medicine
mi
from
Chicago, IL
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
University of Chicago Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
NorthShore University Health System
mi
from
Evanston, IL
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
NorthShore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Gastroenterology Associates
mi
from
Baton Rouge, LA
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Gastroenterology Associates
mi
from
Baton Rouge, LA
Click here to add this to my saved trials